Prokupets Elena
Known title: DirectorCIK: 0001824823
Associated companies
Transaction History
| CCCC | ▼ Sell | Open Market | 539 | $27K | 9/27/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 1,311 | $66K | 9/27/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 2,115 | $106K | 9/24/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 900 | $45K | 9/24/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 5,926 | $298K | 9/23/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 446 | $23K | 9/23/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 11,801 | $594K | 9/23/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 1,007 | $51K | 9/23/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 3,544 | $178K | 9/22/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 7,004 | $351K | 9/22/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 4,988 | $250K | 9/21/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 5,333 | $267K | 9/21/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 5,152 | $258K | 9/17/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 5,688 | $285K | 9/17/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 346 | $17K | 9/16/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 346 | $17K | 9/16/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 25,807 | $1.3M | 9/16/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 24,193 | $1.2M | 9/15/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 30,000 | $1.5M | 9/15/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 492 | $25K | 9/14/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 492 | $25K | 9/14/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 3,330 | $167K | 9/13/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 3,330 | $167K | 9/13/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 1,230 | $62K | 9/10/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 1,320 | $66K | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.